MedTrace Logo

Expanded Access to Fosigotifator

NCT06594016 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-01-14

No results posted yet for this study

Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Fosigotifator prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Conditions

  • Vanishing White Matter
  • Cree Leukoencephalopathy

Interventions

DRUG

Fosigotifator

Oral

Sponsors & Collaborators

Principal Investigators

  • ABBVIE INC. · AbbVie

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06594016 on ClinicalTrials.gov